Today Merck announced that their MK-8931 has entered a Phase
2/3 clinical trial, a randomized placebo-controlled study which will run for 78
weeks and enroll up to 1700 patients in the phase 3 portion.
There have been concerns lately as to whether or not BACE1
is a viable target for Alzheimers; it will take large studies like this to answer
that question. Practical Fragments wishes them luck.
Posts
3 comments:
According to what I read here: http://www.rxwiki.com/mk-8931 as well as what you're saying, it sounds like targeting proteins is the wave of the future. Keep up the great reporting!
Probably the last throw of the dice for BACE?
Glad to have stumbled upon your blog, even though the technical discussion is over my head. I follow mk-8931 and the Astex fragment discovery programs closely on my BiotechDueDiligence website so I am always glad to have another source. It is interesting to note that this program dates back to a screening deal between SGP and Pharmacopeia PCOP, which was later bought by Ligand Pharma LGND, who now stands to receives royalties on MK-8931
Post a Comment